Introduction

The aim of this educational programme was to provide a balanced overview on a novel approach to reduce residual CV risk in patients with increase cardiovascular and renal risk, namely BET inhibition. BET refers to a bromodomain and extra-terminal domain of regulatory proteins. Its inhibition modifies gene expression via epigenetic mechanisms.. This symposium was held during the 54th ERA EDTA Congress in Madrid, Spain on June 5, 2017

Educational objectives

• To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
• To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
• To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
• To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Agenda

Co-chairman

• Carmine Zoccali, MD CNR-IFC, Reggio Cal, Italy
• Vincent M Brandenburg, MD Aachen, Germany

Topics

• Introduction - Vincent M Brandenburg, MD, Aachen, Germany
• The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk? - Luis M Ruilope, MD, Hospital 12 de Octubre Madrid, Spain
• Epigenetics as a novel strategy in cardiovascular and renal risk reduction: A closer look at BET as pathway for inhibition - Marta Ruiz-Ortega, Fundación Jiménez Díaz,Madrid, Spain
• BET inhibition in renal and cardiovascular disease: What is the clinical roadmap? - Kamyar Kalantar-Zade, MD, UC Irvine School of Medicine, Irvine, Ca, USA
• Discussion & summary - Carmine Zoccali, MD, Reggio Cal, Italy

CME accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit

Funding

The symposium was supported by an unrestricted educational grant from Resverlogix Corp